151 related articles for article (PubMed ID: 34465264)
1. Analytical similarity assessment of MYL-1402O to reference Bevacizumab.
Goyal P; Vats B; Subbarao M; Honnappa CG; Kabadi P; Rohil S; Bera A; Mehta GR; Pai H; Adhikari L; Tagore R; Sharma S; Venkatachala R; Nair P; Annegowda S; Sahu A; Trivedi S; Shastri N; Gokhale Y; Thomas R; Thakur A; Mohan D; Rao K U; Melarkode R; Ullanat R
Expert Opin Biol Ther; 2022 Feb; 22(2):271-298. PubMed ID: 34465264
[TBL] [Abstract][Full Text] [Related]
2. MYL-1402O: A Bevacizumab Biosimilar.
Lee A
Target Oncol; 2022 Jan; 17(1):85-88. PubMed ID: 34910269
[TBL] [Abstract][Full Text] [Related]
3. Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer.
Socinski MA; Waller CF; Idris T; Bondarenko I; Luft A; Beckmann K; Vishweswaramurthy A; Loganathan S; Donnelly C; Hummel MA; Shapiro R; Woods M; Rao A; Nayak VG; Ranganna G; Barve A
Ther Adv Med Oncol; 2021; 13():17588359211045845. PubMed ID: 34819997
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin
Owen JS; Rackley RJ; Hummel MA; Roepcke S; Huang H; Liu M; Idris TA; Murugesan SMN; Marwah A; Loganathan S; Ranganna G; Barve A; Waller CF; Socinski MA
Eur J Drug Metab Pharmacokinet; 2023 Nov; 48(6):675-689. PubMed ID: 37792130
[TBL] [Abstract][Full Text] [Related]
5. A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab.
Hummel M; Bosje T; Shaw A; Liu MS; Barve A; Kothekar M; Socinski MA; Waller CF
J Cancer Res Clin Oncol; 2022 Feb; 148(2):487-496. PubMed ID: 33866430
[TBL] [Abstract][Full Text] [Related]
6. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
Peraza MA; Rule KE; Shiue MHI; Finch GL; Thibault S; Brown PR; Clarke DW; Leach MW
Regul Toxicol Pharmacol; 2018 Jun; 95():236-243. PubMed ID: 29574193
[TBL] [Abstract][Full Text] [Related]
7. Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine.
Goyal P; Pai HV; Kodali P; Vats B; Vajpai N; Annegowda S; Mane K; Mohan S; Saxena S; Veerabhadraia AB; Palande M; Nair PS; More DC; Karudumpa UR; Jyothirmai K; Bhattacharya A; Almeida F; Khyade SG; Gouda S; Ranayhossaini DJ; Moole PR; Smith JP; Barve A; Melarkode R; Ullanat R
PLoS One; 2021; 16(6):e0253168. PubMed ID: 34133466
[TBL] [Abstract][Full Text] [Related]
8. Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab.
Cao D; Deng C; Wang G; Mei X; Xie J; Liu Y; Liu Y; Yang Y; Li S; Liu C
Drugs R D; 2023 Sep; 23(3):267-288. PubMed ID: 37479945
[TBL] [Abstract][Full Text] [Related]
9. FKB238: A Bevacizumab Biosimilar.
Syed YY
Clin Drug Investig; 2021 Sep; 41(9):825-828. PubMed ID: 34347284
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer.
Hamada S; Ichiyasu H; Ikeda T; Inaba M; Kashiwabara K; Sadamatsu T; Sato N; Akaike K; Okabayashi H; Saruwatari K; Tomita Y; Saeki S; Hirata N; Yoshinaga T; Fujii K
BMC Pulm Med; 2019 Apr; 19(1):72. PubMed ID: 30940113
[TBL] [Abstract][Full Text] [Related]
11. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.
Seo N; Polozova A; Zhang M; Yates Z; Cao S; Li H; Kuhns S; Maher G; McBride HJ; Liu J
MAbs; 2018; 10(4):678-691. PubMed ID: 29553864
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound-enhanced bevacizumab release from echogenic liposomes for inhibition of atheroma progression.
Klegerman ME; Naji AK; Haworth KJ; Zou Y; Golunski E; Peng T; Britton GL; Huang SL; Holland CK; McPherson DD
J Liposome Res; 2016; 26(1):47-56. PubMed ID: 25865025
[TBL] [Abstract][Full Text] [Related]
13. Part 1: Physicochemical characterization of bevacizumab in undiluted 25 mg/mL drug product solutions: Comparison of originator with a biosimilar candidate.
Arvinte T; Palais C; Poirier E; Cudd A; Rajendran S; Brokx S; Dowd J
J Pharm Biomed Anal; 2019 Oct; 175():112742. PubMed ID: 31344647
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Liu M; Luo N; Fang Z; Liu Q; Yi F; Wei Y; Zhang X; Zhang W
J Clin Pharm Ther; 2022 Feb; 47(2):157-167. PubMed ID: 34617297
[TBL] [Abstract][Full Text] [Related]
15. SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation.
Peeters M; Lipp HP; Park M; Yoon YC; Arnold D
Future Oncol; 2023 Feb; 19(6):427-450. PubMed ID: 36883661
[TBL] [Abstract][Full Text] [Related]
16. Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion.
Tamiya M; Tamiya A; Yamadori T; Nakao K; Asami K; Yasue T; Otsuka T; Shiroyama T; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Kawase I; Hirashima T
Med Oncol; 2013; 30(3):676. PubMed ID: 23925664
[TBL] [Abstract][Full Text] [Related]
17. Correction to: MYL-1402O: A Bevacizumab Biosimilar.
Lee A
Target Oncol; 2022 May; 17(3):379. PubMed ID: 35437710
[No Abstract] [Full Text] [Related]
18. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration.
Fan F; Samuel S; Gaur P; Lu J; Dallas NA; Xia L; Bose D; Ramachandran V; Ellis LM
Br J Cancer; 2011 Apr; 104(8):1270-7. PubMed ID: 21407219
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases.
Tokito T; Shukuya T; Akamatsu H; Taira T; Ono A; Kenmotsu H; Naito T; Murakami H; Takahashi T; Endo M; Yamamoto N
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1493-8. PubMed ID: 23532208
[TBL] [Abstract][Full Text] [Related]
20. Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO
Zhu R; Wang Z; Liang P; He X; Zhuang X; Huang R; Wang M; Wang Q; Qian Y; Wang S
Acta Biomater; 2017 Nov; 63():163-180. PubMed ID: 28923539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
